Recent developments in chemodrug-loaded nanomedicines and their application in combination cancer immunotherapy

Shim, Nayeon; Cho, Hanhee; Jeon, Seong Ik; Kim, Kwangmeyung

doi:10.1007/s40005-023-00646-7

Cited by 6 publications

(1 citation statement)

References 229 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To overcome the limitations mentioned above, employing a nanocarrier for drug delivery systems could be the optimal choice [ 10 , 44 , 45 ]. Tumor accumulation in nanocarriers, facilitated by the enhanced permeation and retention (EPR) effect, is well-documented and helps in reducing off-target toxicity [ 46 , 47 , 48 , 49 ].…”

Section: Introductionmentioning

confidence: 99%

Nano-Delivery of Immunogenic Cell Death Inducers and Immune Checkpoint Blockade Agents: Single-Nanostructure Strategies for Enhancing Immunotherapy

Moon,

Cho,

Kim

2024

Pharmaceutics

Self Cite

View full text Add to dashboard Cite

Cancer immunotherapy has revolutionized oncology by harnessing the patient’s immune system to target and eliminate cancer cells. However, immune checkpoint blockades (ICBs) face limitations such as low response rates, particularly in immunologically ‘cold’ tumors. Enhancing tumor immunogenicity through immunogenic cell death (ICD) inducers and advanced drug delivery systems represents a promising solution. This review discusses the development and application of various nanocarriers, including polymeric nanoparticles, liposomes, peptide-based nanoparticles, and inorganic nanoparticles, designed to deliver ICD inducers and ICBs effectively. These nanocarriers improve therapeutic outcomes by converting cold tumors into hot tumors, thus enhancing immune responses and reducing systemic toxicity. By focusing on single-nanoparticle systems that co-deliver both ICD inducers and ICBs, this review highlights their potential in achieving higher drug concentrations at tumor sites, improving pharmacokinetics and pharmacodynamics, and facilitating clinical translation. Future research should aim to optimize these nanocarrier systems for better in vivo performance and clinical applications, ultimately advancing cancer immunotherapy.

show abstract